JP2019507114A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507114A5
JP2019507114A5 JP2018535156A JP2018535156A JP2019507114A5 JP 2019507114 A5 JP2019507114 A5 JP 2019507114A5 JP 2018535156 A JP2018535156 A JP 2018535156A JP 2018535156 A JP2018535156 A JP 2018535156A JP 2019507114 A5 JP2019507114 A5 JP 2019507114A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
methyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535156A
Other languages
English (en)
Japanese (ja)
Other versions
JP6956725B2 (ja
JP2019507114A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012457 external-priority patent/WO2017120422A1/en
Publication of JP2019507114A publication Critical patent/JP2019507114A/ja
Publication of JP2019507114A5 publication Critical patent/JP2019507114A5/ja
Priority to JP2021164033A priority Critical patent/JP7238065B2/ja
Application granted granted Critical
Publication of JP6956725B2 publication Critical patent/JP6956725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535156A 2016-01-08 2017-01-06 抗増殖化合物、ならびにそれらの薬学的組成物及び使用 Active JP6956725B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021164033A JP7238065B2 (ja) 2016-01-08 2021-10-05 抗増殖化合物、ならびにそれらの薬学的組成物及び使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276763P 2016-01-08 2016-01-08
US62/276,763 2016-01-08
PCT/US2017/012457 WO2017120422A1 (en) 2016-01-08 2017-01-06 Antiproliferative compounds, and their pharmaceutical compositions and uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021164033A Division JP7238065B2 (ja) 2016-01-08 2021-10-05 抗増殖化合物、ならびにそれらの薬学的組成物及び使用

Publications (3)

Publication Number Publication Date
JP2019507114A JP2019507114A (ja) 2019-03-14
JP2019507114A5 true JP2019507114A5 (US07846941-20101207-C00217.png) 2020-02-20
JP6956725B2 JP6956725B2 (ja) 2021-11-02

Family

ID=59274385

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535156A Active JP6956725B2 (ja) 2016-01-08 2017-01-06 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
JP2021164033A Active JP7238065B2 (ja) 2016-01-08 2021-10-05 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
JP2023031138A Pending JP2023071846A (ja) 2016-01-08 2023-03-01 抗増殖化合物、ならびにそれらの薬学的組成物及び使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021164033A Active JP7238065B2 (ja) 2016-01-08 2021-10-05 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
JP2023031138A Pending JP2023071846A (ja) 2016-01-08 2023-03-01 抗増殖化合物、ならびにそれらの薬学的組成物及び使用

Country Status (30)

Country Link
US (4) US9938254B2 (US07846941-20101207-C00217.png)
EP (2) EP3399978B1 (US07846941-20101207-C00217.png)
JP (3) JP6956725B2 (US07846941-20101207-C00217.png)
KR (1) KR20180099712A (US07846941-20101207-C00217.png)
CN (2) CN113662941A (US07846941-20101207-C00217.png)
AR (1) AR107321A1 (US07846941-20101207-C00217.png)
AU (3) AU2017205636B2 (US07846941-20101207-C00217.png)
BR (1) BR112018013761A2 (US07846941-20101207-C00217.png)
CA (1) CA3010796A1 (US07846941-20101207-C00217.png)
CL (1) CL2018001837A1 (US07846941-20101207-C00217.png)
CO (1) CO2018008304A2 (US07846941-20101207-C00217.png)
CY (1) CY1123574T1 (US07846941-20101207-C00217.png)
DK (1) DK3399978T3 (US07846941-20101207-C00217.png)
EA (1) EA037517B1 (US07846941-20101207-C00217.png)
EC (1) ECSP18050782A (US07846941-20101207-C00217.png)
ES (2) ES2957477T3 (US07846941-20101207-C00217.png)
HR (1) HRP20201789T1 (US07846941-20101207-C00217.png)
HU (1) HUE051231T2 (US07846941-20101207-C00217.png)
IL (1) IL260377B (US07846941-20101207-C00217.png)
LT (1) LT3399978T (US07846941-20101207-C00217.png)
MX (1) MX367669B (US07846941-20101207-C00217.png)
PL (1) PL3399978T3 (US07846941-20101207-C00217.png)
PT (1) PT3399978T (US07846941-20101207-C00217.png)
RS (1) RS61070B1 (US07846941-20101207-C00217.png)
SA (1) SA518391967B1 (US07846941-20101207-C00217.png)
SG (2) SG11201805779TA (US07846941-20101207-C00217.png)
SI (1) SI3399978T1 (US07846941-20101207-C00217.png)
TW (2) TWI717448B (US07846941-20101207-C00217.png)
WO (1) WO2017120422A1 (US07846941-20101207-C00217.png)
ZA (1) ZA201804423B (US07846941-20101207-C00217.png)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
ES2956767T3 (es) 2016-01-08 2023-12-27 Celgene Corp Formulaciones de 2-(4-clorofenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
HUE051231T2 (hu) * 2016-01-08 2021-03-01 Celgene Corp Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
UA124529C2 (uk) 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
CN115282149A (zh) 2016-06-06 2022-11-04 细胞基因公司 用抗癌剂治疗血液恶性肿瘤
PT3551627T (pt) 2016-12-08 2022-04-06 H Hoffnabb La Roche Ag Novos derivados de éter isoxazolílico enquanto moduladores alostéricos positivos de gaba a α5
AU2020283744A1 (en) * 2019-05-24 2021-12-09 Biotheryx, Inc. Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
RU2230550C2 (ru) 1998-01-16 2004-06-20 Такеда Кемикал Индастриз, Лтд. Композиции длительного высвобождения, способ их получения и применение
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
JP4296312B2 (ja) * 2003-01-30 2009-07-15 学校法人日本大学 新規トリテルペン化合物及び該化合物を有効成分とする抗ガン・免疫増強剤
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
BRPI0716092A2 (pt) * 2006-08-30 2013-09-17 Celgene Corp composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
WO2008138843A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
NZ592425A (en) 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN101735276A (zh) * 2009-12-17 2010-06-16 廖国超 水溶性磷酸单酯衍生物及其应用
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
AU2012236655B2 (en) * 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
TW201534305A (zh) * 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
HUE051231T2 (hu) * 2016-01-08 2021-03-01 Celgene Corp Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai

Similar Documents

Publication Publication Date Title
JP2019507114A5 (US07846941-20101207-C00217.png)
JP2020505396A5 (US07846941-20101207-C00217.png)
HRP20201789T1 (hr) Antiproliferativni spojevi, te njihovi farmaceutski pripravci i uporabe
JP2020505395A5 (US07846941-20101207-C00217.png)
JP2019529484A5 (US07846941-20101207-C00217.png)
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
JP2019517487A5 (US07846941-20101207-C00217.png)
JP2020521740A5 (US07846941-20101207-C00217.png)
JP2019094345A5 (US07846941-20101207-C00217.png)
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP2019518741A5 (US07846941-20101207-C00217.png)
JP2013512903A5 (US07846941-20101207-C00217.png)
JP2018522879A5 (US07846941-20101207-C00217.png)
JP2016523974A5 (US07846941-20101207-C00217.png)
JP2019502708A5 (US07846941-20101207-C00217.png)
JP2015514808A5 (US07846941-20101207-C00217.png)
JP2005536475A5 (US07846941-20101207-C00217.png)
JP2011509309A5 (US07846941-20101207-C00217.png)
JP2016506962A5 (US07846941-20101207-C00217.png)
JP2015504067A5 (US07846941-20101207-C00217.png)
RU2007116987A (ru) Новые соединения
JP2017526677A5 (US07846941-20101207-C00217.png)
JP2013542267A5 (US07846941-20101207-C00217.png)
JP2020527173A5 (US07846941-20101207-C00217.png)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы